SCHEMBL2942295

SCHEMBL2942295

O=C(/C=C/c1cccc(C(F)(F)F)c1)N1CCC2(CC1)NCC(=O)N2Cc1ccccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.44
GPR183 P32249 2/20 0.44
CDC25B P30305 1/20 0.42
CCR2 P41597 3/20 0.42
ALDH1A1 P00352 2/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDM4E B2RXH2 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
MAOB P27338 1/20 0.38
DCUN1D1 Q96GG9 1/20 0.38
S1PR1 P21453 1/20 0.38
S1PR5 Q9H228 1/20 0.38
POLB P06746 2/20 0.38
GAA P10253 1/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1801521 1.00 LMNA (0.44) LMNAGPR183CDC25BCCR2ALDH1A1
SCHEMBL1803359 0.81 USP2 (0.52) ALDH1A1SMN1; SMN2
SCHEMBL1801500 0.79 TACR1 (0.42) LMNAALDH1A1SMN1; SMN2KDM4EDCUN1D1
SCHEMBL1802929 0.76 KDM4E (0.45) LMNAALDH1A1KDM4EMEN1KMT2A
SCHEMBL1801574 0.76 RIPK1 (0.47) LMNAGPR183ALDH1A1TP53SMN1; SMN2
SCHEMBL1797061 0.74 RIPK1 (0.50) MEN1KMT2A
SCHEMBL1803894 0.73 RIPK1 (0.51) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL5156459 0.73 ALDH1A1 (0.48) LMNAALDH1A1SMN1; SMN2KDM4EMEN1
SCHEMBL1802807 0.73 RIPK1 (0.41) LMNAGPR183ALDH1A1TP53KDM4E
SCHEMBL1799247 0.72 ALDH1A1 (0.53) LMNAALDH1A1SMN1; SMN2KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730147-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2010-02-03 EP claimed
WO-2005095402-A9 SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2009-06-11 WO claimed
EP-1730147-A1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY Grünenthal GmbH (DE) 2006-12-13 EP claimed
WO-2005095402-A1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY Grünenthal GmbH (DE) 2005-10-13 WO claimed
EP-1730147-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2010-02-03 EP disclosed
WO-2005095402-A9 SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2009-06-11 WO disclosed
EP-1730147-A1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY Grünenthal GmbH (DE) 2006-12-13 EP disclosed
WO-2005095402-A1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY Grünenthal GmbH (DE) 2005-10-13 WO disclosed